" class="no-js "lang="en-US"> Orbit Discovery - Medtech Alert
Wednesday, September 27, 2023
Orbit Discovery | Pharmtech Focus

Orbit Discovery

About Orbit Discovery

Orbit Discovery

Orbit develop and apply innovative drug discovery platforms defined by a unique peptide display engine that deliver novel, functional, biologically relevant peptide therapeutic leads. The Orbit peptide display engine is uniquely able to address cell-based targets and thereby screen targets in relevant contexts. Peptide leads are key starting points for the development of peptide, peptidomimetic and small molecule therapeutics as well as bioconjugates for cell targeting and cargo delivery. Founded in late 2015 as a spin-out from Oxford University based on the work of Professors Graham Ogg and Terry Rabbitts. We have a pipeline of novel targets in in-house programmes and we work in collaboration with others in industry and academia to make our technology as accessible as possible.

Related Story

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

April 3 2023

Evergreen Discovery, a leading radiopharmaceutical drug development company with a focus on the treatment and […]

Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics

February 1 2023

Orbit Discovery, a leader in the discovery of therapeutic peptide hits, today announced it has […]

Orbit Discovery Awarded Innovate UK Grant to Expand High Throughput Cell-based Functional Screening Platform Capabilities in Peptide Drug Discovery

June 14 2022

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics […]